Clindamycin (Standard)

CAT: 0804-HY-B1455R-01Size: 5 mgDry Ice: NoHazardous: No

1 / 1

CAT#:0804-HY-B1455R-01Size:5 mg

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

Clindamycin (Standard) is the analytical standard of Clindamycin. This product is intended for research and analytical applications. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs) . Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA) . Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla) . Clindamycin also can be used for researching malaria[1][2].

CAS Number

18323-44-9

UNSPSC

12352005

Target

Antibiotic; Bacterial; Parasite; Reference Standards

Type

Reference Standards

Related Pathways

Anti-infection; Others

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/clindamycin-standard.html

Smiles

CN(C[C@H](CCC)C1)[C@@H]1C(N[C@@]([C@@H](Cl)C)([H])[C@@]2([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)=O

Molecular Formula

C18H33ClN2O5S

Molecular Weight

424.98

References & Citations

[1]Hodille E, et al. Clindamycin suppresses virulence expression in inducible clindamycin-resistant Staphylococcus aureus strains. Ann Clin Microbiol Antimicrob. 2018 Oct 20;17 (1) :38.|[2]Kremsner PG. Clindamycin in malaria treatment. J Antimicrob Chemother. 1990 Jan;25 (1) :9-14.|[3]Kishi K, et al. Clindamycin suppresses endotoxin released by ceftazidime-treated Escherichia coli O55:B5 and subsequent production of tumor necrosis factor alpha and interleukin-1 beta. Antimicrob Agents Chemother. 1999 Mar;43 (3) :616-22.|[4]Veringa EM, et al. Clindamycin at subinhibitory concentrations enhances antibody- and complement-dependent phagocytosis by human polymorphonuclear leukocytes of Staphylococcus aureus. Chemotherapy. 1987;33 (4) :243-9. |[5]Naal FD, et al. The effects of clindamycin on human osteoblasts in vitro. Arch Orthop Trauma Surg. 2008 Mar;128 (3) :317-23.|[6]Faggion PI, et al. Is the penetration of clindamycin into the masseter muscle really enough to treat odontogenic infections? Clin Oral Investig. 2021 May;25 (5) :3257-3266. |[7]Yang SH, Lee MG. Dose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: contribution of gastric first-pass effect to low bioavailability. Int J Pharm. 2007 Mar 6;332 (1-2) :17-23.|[8]Hirata N, et al. Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of inflammatory cytokines. Antimicrob Agents Chemother. 2001 Sep;45 (9) :2638-42.

Shipping Conditions

Room temperature

Scientific Category

Reference Standards

Related Products

Catalog	Name
HY-B1064R-01	Clindamycin phosphate (Standard)
HY-B0408AR-01	Clindamycin (hydrochloride) (Standard)
HY-B1454R	Clindamycin palmitate (hydrochloride) (Standard)
HY-N7118R	Clindamycin (hydrochloride monohydrate) (Standard)
HY-B1455-01	Clindamycin
HY-127059-01	Clindamycin Sulfoxide
HY-B0408A-01	Clindamycin (hydrochloride)
HY-W777995-01	Clindamycin B
HY-B1064-01	Clindamycin phosphate
HY-B1455S	Clindamycin-d3 (hydrochloride)

Alternative Products

Catalog	Name
B1707-100	Clindamycin

Clindamycin (Standard)

Related Products

Alternative Products

Popular Products